Oruka Therapeutics, Inc.
ORKA
$41.62
-$0.13-0.31%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 2.29% | -23.21% | -17.02% | 37.11% | -16.66% |
| Total Depreciation and Amortization | 40.00% | 5.26% | 18.75% | -13.51% | 68.18% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -61.21% | 150.26% | 17.50% | -26.18% | -59.49% |
| Change in Net Operating Assets | 659.80% | 73.70% | 24.56% | -160.27% | 151.72% |
| Cash from Operations | -4.59% | 6.67% | -10.91% | 13.32% | 13.45% |
| Capital Expenditure | 36.36% | -191.18% | -161.54% | 63.07% | 79.42% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 82.05% | -2,600.00% | -88.59% | 111.91% | -- |
| Cash from Investing | 82.02% | -2,619.53% | -88.66% | 111.91% | -210,407.31% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -99.82% | 155,778.90% | -- | -- | -91.05% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -99.82% | 155,778.90% | -- | -- | -90.48% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -271.40% | 242.26% | -182.63% | 106.40% | -186.85% |